SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches a pivotal oral presentation at the Digestive Disease Week conference. The community is heavily focused on the company's potential to showcase breakthrough pancreatic cancer data, with many shareholders anticipating that these clinical results will act as a major catalyst for the stock.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the current price represents a deep-value opportunity or a value trap, with the community closely tracking its pivot into agentic AI orchestration and enterprise integration partnerships. While some participants express frustration over persistent share price weakness and perceived manipulation, others are aggressively accumulating shares, pointing to the company's strong cash position, lack of debt, and potential for long-term growth as the market rotates toward quality AI software.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is trending as part of a broader rotation into established, high-beta memecoin narratives, with the community actively rallying around its OG status and viral potential. Enthusiasts are highlighting the asset's cultural durability while comparing it to other memetic projects and speculating on future liquidity shifts within the Solana ecosystem.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Cronos ($CRO) is experiencing heightened community activity as investors weigh its potential for institutional adoption through upcoming ETF filings against persistent concerns regarding long-term token dilution. Discussions are split between optimism over its integration into the broader DeFi ecosystem and frustration with its stagnant price performance relative to other major assets.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing renewed trading activity driven by speculative interest in its IoT and data democracy narratives alongside broad crypto market volatility. Community members remain polarized, with long-term holders focusing on accumulation and ecosystem development while skeptics continue to voice concerns over price stagnation and lack of official project updates.

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is generating investor interest as a premier leader in life sciences, buoyed by the recent acquisition of Clario Holdings to bolster its AI-driven clinical trial capabilities. The community is actively debating the company's valuation against broader healthcare sector headwinds, with many analysts maintaining bullish outlooks based on its essential role in research and diagnostics infrastructure.

Eversource Energy engages in the generation, transmission, and distribution of natural gas and electricity. It operates through the following segments: Electric Distribution, Electric Transmission, Natural Gas Distribution, Water Distribution, and Other. The Electric Distribution segment distributes electricity to retail customers. The Electric Transmission segment owns and maintains transmission facilities through CL&P, NSTAR Electric, PSNH, and WMECO. The Natural Gas Distribution segment transmits and distributes natural gas to retail customers. The Water Distribution segment operates five separate regulated water utilities in Connecticut, Massachusetts, and New Hampshire. The company was founded on July 1, 1966, and is headquartered in Springfield, MA.

Eversource Energy

Eversource Energy (ES) is currently in focus as investors analyze its long-term growth strategy, recent earnings reports, and ongoing regulatory headwinds within the New England energy sector. While the stock's defensive dividend profile remains a talking point, community discussion is centered on the company's efforts to balance clean energy infrastructure investments with the challenges of managing project liabilities and regulatory scrutiny.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy Inc. is trending as investors digest a recent short-seller report, with the community largely rallying behind the company's domestic manufacturing strategy and institutional support. Traders are actively debating the stock's potential for a short squeeze as it maintains strong momentum amid significant interest in U.S. solar infrastructure and data center power demand.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is drawing significant community interest as investors weigh its role in the emerging real-world asset (RWA) space and its potential institutional adoption alongside the upcoming Clarity Act. Traders remain divided, with some actively accumulating during recent price fluctuations while others debate whether current network growth will translate into a long-term price breakthrough.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing high social media engagement as investors speculate on potential breakout levels and debate its long-term viability compared to other meme tokens. The community is actively tracking its price action, with many discussing its volatility, historical patterns, and potential for a significant upward move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company’s outstanding shares will be reduced from roughly 929.5 million to around 18.6 million shares.</li><li>Kala Bio had until July 20, 2026, to regain compliance with Nasdaq’s minimum price requirement of $1 per share.</li><li>The Board of Directors had the option to effect a reverse stock split in a ratio ranging from 1-for-2 to 1-for-100.&nbsp;</li></ul>Shares of Kala Bio (KALA) plunged more than 27% to a record low on Thursday after the company announced a reverse stock split, following months of relentless decline that kept the stock from reclaiming the crucial $1 threshold even once this year.Kala Bio said it will implement a 1-for-50 reverse stock split, effective after the closing bell on May 8. The stock will begin trading on a split-adjusted basis on Nasdaq from May 11.Following the move, the company’s outstanding shares will be reduced from roughly 929.5 million to around 18.6 million shares.<h2 class="st-heading-2">KALA Shares Fell Below $1 In December 2025</h2>Kala Bio has until July 20, 2026, to regain compliance with Nasdaq’s minimum price requirement of $1 per share. It had received a notice from the exchange in January for failing to trade above the threshold for 30 straight business days between Dec. 3, 2025, and Jan. 16, 2026.Following the notice, the company held a special stockholder meeting on January 30, at which shareholders approved the Board of Directors’ authorization to effect a reverse stock split at a ratio of 1-for-2 to 1-for-100.<h2 class="st-heading-2">Retail Urges Buying The Dip</h2>Despite the intraday slump, retail sentiment on Stocktwits changed to ‘neutral’ from ‘bearish’ a day earlier.Chatter was largely positive, with one user stating that they would buy more shares.<stembedurl>https://stocktwits.com/7traderja/message/652575680</stembedurl><a href="https://stocktwits.com/symbol/KALA">KALA shares</a> have plummeted 86% so far this year.<h2 class="st-heading-2">‘Palantir For Biotech’</h2>Earlier this year, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-did-kala-stock-surge-in-pre-market-today/cZdAxnCRIJk">unveiled</a> the Researgency.ai platform designed for biotech and pharmaceutical companies to help automate research and drug development tasks.It can support clinical trials, regulatory document management, drug safety tracking, and commercial launch preparation, the company said.“We are building the Palantir for biotech,” CEO Avi Minkowitz stated.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/atara-atra-stock-rises-fda-meeting-cancer-treatment/cZXbLfKReQ7">ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark

Kala Bio said it will implement a 1-for-50 reverse stock split, effective after the closing bell on May 8.

Equity

KALA BIO (NASDAQ:KALA) Posts Quarterly Earnings Results

KALA BIO (NASDAQ:KALA - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.86 earnings per share (EPS) for the quarter...

KALA BIO, Inc. (NASDAQ:KALA) Sees Significant Drop in Short Interest

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totaling 1,137,572 shares, a drop of 83.3% from...

KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,830,724 shares...

KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) saw a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 975,765 shares, a growth...

AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. $KALA, $TGNT, $DOMO, $TSSI, $CYN, $AUNA, $VACHU

<ul class="summary-bullets"><li>Researgency enables firms to deploy AI tools for research, clinical trials, managing regulatory documents, and tracking drug safety.</li><li>Earlier this month, KALA signed a platform development and exclusive license agreement with Younet AI for Researgency.</li><li>The company said that while it will provide the AI platform, clients retain full control and ownership of their data.</li></ul>Shares of KALA BIO Inc. (KALA) shed most of their early gains to trade 25% higher on Wednesday, after the biotech company said it expects to ship its first commercial artificial intelligence product, the Researgency.ai platform, within 14 days.Researgency enables biotech and pharmaceutical companies to design and deploy AI tools to monitor research, support clinical trials, manage regulatory documents, track drug safety, and prepare commercial launch materials.The company said the platform is now fully live following a rebrand and is designed to deploy specialized AI agents to automate complex, repetitive tasks in drug development.“We are building the Palantir for biotech. Our first agent ships in 14 days, and our team is fired up. This is the beginning of something big,” said Avi Minkowitz, CEO of Kala.&nbsp;<h2 class="st-heading-2">Partnership With Younet AI To Develop Researgency</h2>Earlier this month, KALA signed a platform development and exclusive license agreement with Younet AI for Researgency. The agreement grants KALA access to the platform for an initial 12-month period, with the option to extend in one-year terms.KALA will provide the AI platform, specialized biomedical agents, and ongoing optimization, while clients retain full control and ownership of their data. The company said the platform targets small and mid-sized biotech firms seeking secure AI tools without relying on public AI services.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/KALA_jpg_f4e658a281.webp" alt="KALA.jpg">One user expects the stock to climb above $1 this week. It is currently at $0.36.<stembedurl>https://stocktwits.com/Ozunoy/message/647231891</stembedurl>Another user believes the development is “huge,” and that the company is “just getting started.”<stembedurl>https://stocktwits.com/jengtap/message/647229239</stembedurl><a href="https://stocktwits.com/symbol/KALA">KALA shares</a> have shed around 34% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-jumps-barclays-says-market-is-underestimating-opportunity-from-new-products/cZdr3RoRIJH">HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating&nbsp;Opportunity From New Products</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

Why Did KALA Stock Surge 25% Today?

KALA BIO Inc company said that it is ready to deploy its new AI platform, Researgency, within 14 days.

The company said that it is ready to deploy its new AI platform, Researgency, within 14 days.

KALA BIO, Inc. (NASDAQ:KALA) Given Average Rating of "Hold" by Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One...

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	-$1.70	-$1.71	-0.39%	MISSED
Q1 '25	-$2.03	-$1.41	30.54%	BEAT
Q4 '24	-$2.28	-$1.74	23.68%	BEAT
Q3 '24	-$2.43	-$1.93	20.58%	BEAT
Q2 '24	-$4.41	-$3.16	28.26%	BEAT

KALA
KALA BIO Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '25

Historical Earnings

Latest KALA News

KALAKALA BIO Inc